<DOC>
	<DOCNO>NCT00581789</DOCNO>
	<brief_summary>- To determine safety maximally tolerate dose sunitinib plus erlotinib patient non-small cell lung cancer ( NSCLC ) . - To determine response sunitinib plus erlotinib patient non-small cell lung cancer .</brief_summary>
	<brief_title>Erlotinib Sunitinib NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically proven stage IIIB ( pleural effusion pericardial effusion ) IV ( either primary recurrent ) NSCLC ( except squamous cell histology ) . Measurable disease per RECIST Life expectancy least 12 week . Adequate bone marrow , hepatic renal function ECOG performance status 0 , 1 2 . One one prior treatment chemotherapy regimen , include platinum base regimen advance disease ( Stage IIIB malignant effusion Stage IV ) . Signed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment . Female patient must surgically sterile , postmenopausal agree use effective contraception period therapy . Male patient must surgically sterile agree use effective contraception period therapy . Squamous cell histology . History untreated brain metastasis Prior treatment &gt; 1 systemic chemotherapybased regimen advanced disease ( Stage IIIB malignant effusion Stage IV ) . Prior treatment receptor tyrosine kinase inhibitor , VEGF inhibitor , angiogenic inhibitor ( include limit bevacizumab , sunitinib , erlotinib , gefitinib , thalidomide ) . Prior chemotherapy , radiation therapy , surgery , investigational agent within 4 week prior study entry , except palliative radiation therapy nontarget lesion ( must complete 2 week prior study enrollment ) . Eligibility patient receive medication substance know induce inhibit CYP3A4 /or potential affect activity pharmacokinetics sunitinib erlotinib determine follow review case Principal Investigator . NCI CTCAE grade 3 hemorrhage within 4 week start therapy . Ongoing treatment warfarin Prior treatment highdose chemotherapy require stem cell rescue . Prior irradiation &gt; 25 % bone marrow ( whole pelvis = 25 % ) . Diagnosis within prior 3 year second malignancy , except basal cell carcinoma , squamous cell skin carcinoma situ carcinoma completely treat without evidence recurrent disease 12 month . Current treatment another therapeutic clinical trial receipt another investigative agent within 4 week study entry . Any follow within 12 month prior start study treatment : myocardial infarction , unstable angina , coronary/peripheral artery bypass graft , congestive heart failure , cerebrovascular accident include transient ischemic attack , pulmonary embolus . Hypertension ( &gt; 150/100mmHg ) control standard antihypertensive agent . Ongoing cardiac dysrhythmias grade &gt; 2 , â‰¥ grade 3 atrial fibrillation , QTc interval &gt; 450 msec male &gt; 470 msec female . Evidence hemoptysis &lt; 4 week start study treatment . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Other severe acute chronic medical psychiatric condition laboratory abnormality HIVpositive patient Women pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>sunitinib</keyword>
	<keyword>erlotinib</keyword>
	<keyword>phase 1</keyword>
</DOC>